WOLF vs. KPTI

Last updated Jun 9, 2026

WOLF (Wolfspeed, Inc.) and KPTI (Karyopharm Therapeutics Inc.) are both stocks. WOLF operates in Semiconductors (Technology), while KPTI operates in Biotechnology (Healthcare). At a 0.16 correlation, their price movements are largely independent.

Performance

WOLF vs. KPTI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Wolfspeed, Inc. (WOLF) and Karyopharm Therapeutics Inc. (KPTI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, WOLF achieves a 218.32% return, which is significantly higher than KPTI's 15.49% return.

WOLF

• 1D: 0.65%
• 1M: 18.93%
• YTD: 218.32%
• 6M: 141.90%
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

KPTI

• 1D: -6.39%
• 1M: -1.62%
• YTD: 15.49%
• 6M: 44.31%
• 1Y: 89.31%
• 3Y*: -36.47%
• 5Y*: -43.70%
• 10Y*: -23.75%

*Multi-year figures are annualized to reflect compound growth (CAGR)

WOLF vs. KPTI - Yearly Performance Comparison

	2026 (YTD)	2025
WOLF Wolfspeed, Inc.	218.32%	-21.22%
KPTI Karyopharm Therapeutics Inc.	15.49%	15.91%

Correlation

The correlation between WOLF and KPTI is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (All Time) Calculated using the full available price history since Sep 30, 2025	0.16

Fundamentals

Market Cap WOLF : $21.77B KPTI : $210.08M
EPS WOLF : -$11.53 KPTI : -$13.00
PS Ratio WOLF : 10.68 KPTI : 0.84
Total Revenue (TTM) WOLF : $712.50M KPTI : $151.12M
Gross Profit (TTM) WOLF : -$208.10M KPTI : $145.13M
EBITDA (TTM) WOLF : -$1.26B KPTI : -$93.05M

Return for Risk

WOLF vs. KPTI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KPTI

KPTI Risk / Return Rank: 73
KPTI Sharpe Ratio Rank: 72
KPTI Sortino Ratio Rank: 76
KPTI Omega Ratio Rank: 71
KPTI Calmar Ratio Rank: 74
KPTI Martin Ratio Rank: 75

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

WOLF vs. KPTI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Wolfspeed, Inc. (WOLF) and Karyopharm Therapeutics Inc. (KPTI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	WOLF	KPTI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	0.95	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.46	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.28	—
Sharpe Ratio (All Time) Calculated using the full available price history	2.34	-0.27	+2.61

Drawdowns

WOLF vs. KPTI - Drawdown Comparison

The maximum WOLF drawdown since its inception was -58.22%, smaller than the maximum KPTI drawdown of -99.50%. Use the drawdown chart below to compare losses from any high point for WOLF and KPTI.

Drawdown Indicators

	WOLF	KPTI	Difference
Max Drawdown Largest peak-to-trough decline	-58.22%	-99.50%	+41.28%
Max Drawdown (1Y) Largest decline over 1 year	—	-48.36%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-89.32%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-98.36%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-99.15%	—
Current Drawdown Current decline from peak	-24.60%	-98.80%	+74.20%
Average Drawdown Average peak-to-trough decline	-34.87%	-75.28%	+40.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	19.53%	—

Volatility

Volatility by Period

	WOLF	KPTI	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	24.86%	—
Volatility (6M) Calculated over the trailing 6-month period	—	62.32%	—
Volatility (1Y) Calculated over the trailing 1-year period	120.69%	94.32%	+26.37%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	120.69%	94.91%	+25.78%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	120.69%	86.51%	+34.18%

Dividends

WOLF vs. KPTI - Dividend Comparison

Neither WOLF nor KPTI has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

WOLF vs. KPTI - Profitability Comparison

The chart below illustrates the profitability comparison between Wolfspeed, Inc. and Karyopharm Therapeutics Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

WOLF - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Wolfspeed, Inc. reported a gross profit of -27.00M and revenue of 150.20M. Therefore, the gross margin over that period was -18.0%.

KPTI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a gross profit of 33.72M and revenue of 35.07M. Therefore, the gross margin over that period was 96.2%.

WOLF - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Wolfspeed, Inc. reported an operating income of -101.30M and revenue of 150.20M, resulting in an operating margin of -67.4%.

KPTI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported an operating income of -26.76M and revenue of 35.07M, resulting in an operating margin of -76.3%.

WOLF - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Wolfspeed, Inc. reported a net income of -119.90M and revenue of 150.20M, resulting in a net margin of -79.8%.

KPTI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a net income of -22.39M and revenue of 35.07M, resulting in a net margin of -63.9%.

Frequently Asked Questions

Can I hold both WOLF and KPTI in my portfolio?

WOLF and KPTI have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.